Acurx Pharmaceuticals (ACXP) Competitors $4.30 +0.02 (+0.56%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. PASG, MIRA, ENLV, MBRX, XCUR, FBLG, SNYR, MTVA, NEUP, and ALLRShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Passage Bio (PASG), MIRA Pharmaceuticals (MIRA), Enlivex Therapeutics (ENLV), Moleculin Biotech (MBRX), Exicure (XCUR), FibroBiologics (FBLG), Synergy CHC (SNYR), MetaVia (MTVA), Neuphoria Therapeutics (NEUP), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Passage Bio MIRA Pharmaceuticals Enlivex Therapeutics Moleculin Biotech Exicure FibroBiologics Synergy CHC MetaVia Neuphoria Therapeutics Allarity Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Do institutionals & insiders hold more shares of ACXP or PASG? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, ACXP or PASG? Acurx Pharmaceuticals has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Do analysts prefer ACXP or PASG? Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 620.26%. Passage Bio has a consensus price target of $75.67, suggesting a potential upside of 859.02%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Acurx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Passage Bio 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer ACXP or PASG? In the previous week, Acurx Pharmaceuticals had 3 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 1 mentions for Passage Bio. Acurx Pharmaceuticals' average media sentiment score of 0.20 beat Passage Bio's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, ACXP or PASG? Passage Bio is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.40Passage BioN/AN/A-$64.77M-$18.16-0.43 Is ACXP or PASG more profitable? Passage Bio's return on equity of -103.87% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -436.83% -192.25% Passage Bio N/A -103.87%-59.95% SummaryPassage Bio beats Acurx Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.80M$3.35B$6.17B$10.56BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-0.4022.0285.9827.12Price / SalesN/A416.53588.19186.83Price / CashN/A46.3226.3031.10Price / Book6.839.9613.026.67Net Income-$14.10M-$52.42M$3.30B$276.23M7 Day Performance0.33%5.42%4.31%3.65%1 Month Performance5.49%11.59%8.08%10.76%1 Year Performance-89.85%25.84%85.70%40.68% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.7019 of 5 stars$4.30+0.6%$31.00+620.3%-90.0%$6.80MN/A-0.403Short Interest ↓PASGPassage Bio3.3212 of 5 stars$8.14+1.8%$75.67+829.6%-38.9%$25.43MN/A-0.45130News CoverageGap UpMIRAMIRA Pharmaceuticals0.5504 of 5 stars$1.33+0.8%$17.00+1,178.2%+17.4%$25.17MN/A-2.712ENLVEnlivex Therapeutics2.7915 of 5 stars$1.01-1.9%$10.00+890.1%-28.0%$25.02MN/A-1.7470MBRXMoleculin Biotech3.0475 of 5 stars$0.49-1.0%$4.00+721.5%-79.6%$24.35MN/A0.0020XCURExicure1.753 of 5 stars$3.90+2.4%N/A+58.1%$24.07M$500K-1.0150News CoverageGap UpFBLGFibroBiologics2.2173 of 5 stars$0.61+6.7%$12.67+1,969.7%-80.6%$24.03MN/A-1.7010SNYRSynergy CHC3.9059 of 5 stars$2.41-3.6%$10.00+314.9%-40.2%$23.60M$34.83M6.3440MTVAMetaVia2.3928 of 5 stars$0.94-2.9%$7.50+696.5%N/A$23.47MN/A0.008NEUPNeuphoria Therapeutics2.252 of 5 stars$11.86-3.7%$28.00+136.1%N/A$23.14M$15.66M0.00N/AShort Interest ↓ALLRAllarity Therapeutics2.7077 of 5 stars$1.59+0.6%$9.25+481.8%-6.3%$23.10MN/A0.0010 Related Companies and Tools Related Companies Passage Bio Alternatives MIRA Pharmaceuticals Alternatives Enlivex Therapeutics Alternatives Moleculin Biotech Alternatives Exicure Alternatives FibroBiologics Alternatives Synergy CHC Alternatives MetaVia Alternatives Neuphoria Therapeutics Alternatives Allarity Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
